Clinical Trial Update: Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial of a combination including arsenic trioxide, thalidomide, dexamethasone, and ascorbic acid for relapsed or refractory multiple myeloma has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Ascorbic acid (Vitamin C)
• Decadron (Dexamethasone)
• Thalomid (thalidomide)
• Trisenox (arsenic trioxide)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: TERMINATED